Where BPCIA Issues Stand As FDA Approves 25th Biosimilar
On Nov. 15, the U.S. Food and Drug Administration approved Pfizer Inc.'s adalimumab product, a biosimilar to AbbVie Inc.'s Humira, marking the 25th approval of a biosimilar under the Biologics Price...To view the full article, register now.
Already a subscriber? Click here to view full article